Abiopharma

Became an interested party - The Phoenix Investment House Ltd.

Became an interested party – Harel Finance Ltd.

Rating by Maalot +ilA for the issuance of BONDS series Y-het in a scope of up to NIS 800 million par value

BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026

Electrification of the Iepuresti project in Romania has been completed and gradual power supply to the grid has begun, continuation

Clinical trial NCT05375162: enrollment: not set → 304 participants.

Clinical trial NCT07293351: enrollment: not set → 254 participants.

Clinical trial NCT05637112: enrollment: not set → 551 participants.